SpringWorks Therapeutics, Inc., a biopharmaceutical company that specializes in severe rare diseases and cancer, announced that their management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on May 14, 2024. The webcast of the chat can be accessed on the company’s website and a replay will be available for a limited time after the event.
SpringWorks Therapeutics is dedicated to developing life-changing medicines for individuals with severe rare diseases and cancer using a precision medicine approach. With a diversified targeted oncology pipeline, the company is conducting clinical trials in rare tumor types and genetically defined cancers. Their FDA-approved therapy, OGSIVEO®, is used to treat adult patients with desmoid tumors.
Founded in 2017, SpringWorks Therapeutics has rapidly progressed their lead product candidates into late-stage trials and has established collaborations with industry innovators and academia. This strategic approach, combined with operational excellence, has allowed them to create more solutions for cancer patients and unlock the full potential of their portfolio.
SpringWorks Therapeutics is committed to providing hope for patients with severe rare diseases and cancer through innovative therapies that target specific genetic mutations. Their team of experienced scientists and clinicians work tirelessly to develop personalized treatments that are tailored to each patient’s unique needs. With a focus on precision medicine, SpringWorks Therapeutics is poised to revolutionize the way we approach cancer treatment.
For more information about SpringWorks Therapeutics or to learn more about their upcoming fireside chat at the BofA Securities 2024 Health Care Conference, visit their website or contact Kim Diamond, Vice President of Communications and Investor Relations, or Samantha Hilson Sandler, Senior Director of Investor Relations.
